<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Hong T</submitter><funding>National Natural Science Foundation of China</funding><pagination>6622129</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7943292</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>2021</volume><pubmed_abstract>&lt;h4>Objective&lt;/h4>Asprosin, a new adipocytokine, has reportedly been associated with glucose release, dyslipidemia, and insulin resistance (IR). However, the relationship of asprosin with metabolic syndrome (MetS) remains unknown. This study aimed to investigate serum asprosin levels in MetS as well as their association with various metabolic parameters in humans.&lt;h4>Methods&lt;/h4>A total of 131 consecutive patients with MetS, and 162 age-matched, healthy subjects were recruited for this study. Serum asprosin concentrations were determined using the enzyme-linked immunosorbent assay. Lipid profile, glucose, insulin, and inflammatory markers were also measured.&lt;h4>Results&lt;/h4>Serum asprosin levels were higher in subjects with MetS (23.52 [16.70, 32.05] ng/mL) than in controls (16.70 [12.87, 2</pubmed_abstract><journal>International journal of endocrinology</journal><pubmed_title>High Serum Asprosin Levels Are Associated with Presence of Metabolic Syndrome.</pubmed_title><pmcid>PMC7943292</pmcid><funding_grant_id>A2017011</funding_grant_id><funding_grant_id>20201901</funding_grant_id><funding_grant_id>81870595</funding_grant_id><pubmed_authors>Yang J</pubmed_authors><pubmed_authors>Liao ZZ</pubmed_authors><pubmed_authors>Hong T</pubmed_authors><pubmed_authors>Wang YD</pubmed_authors><pubmed_authors>Ran L</pubmed_authors><pubmed_authors>Xiao XH</pubmed_authors><pubmed_authors>Yan B</pubmed_authors><pubmed_authors>Liu JH</pubmed_authors><pubmed_authors>Qi XY</pubmed_authors><pubmed_authors>Bhadel P</pubmed_authors><pubmed_authors>Li JY</pubmed_authors></additional><is_claimable>false</is_claimable><name>High Serum Asprosin Levels Are Associated with Presence of Metabolic Syndrome.</name><description>&lt;h4>Objective&lt;/h4>Asprosin, a new adipocytokine, has reportedly been associated with glucose release, dyslipidemia, and insulin resistance (IR). However, the relationship of asprosin with metabolic syndrome (MetS) remains unknown. This study aimed to investigate serum asprosin levels in MetS as well as their association with various metabolic parameters in humans.&lt;h4>Methods&lt;/h4>A total of 131 consecutive patients with MetS, and 162 age-matched, healthy subjects were recruited for this study. Serum asprosin concentrations were determined using the enzyme-linked immunosorbent assay. Lipid profile, glucose, insulin, and inflammatory markers were also measured.&lt;h4>Results&lt;/h4>Serum asprosin levels were higher in subjects with MetS (23.52 [16.70, 32.05] ng/mL) than in controls (16.70 [12.87, 2</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021</publication><modification>2025-04-04T22:01:17.867Z</modification><creation>2025-04-04T22:01:17.867Z</creation></dates><accession>S-EPMC7943292</accession><cross_references><pubmed>33747078</pubmed><doi>10.1155/2021/6622129</doi></cross_references></HashMap>